News
-
-
COMMUNIQUÉ DE PRESSE
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
IGC Pharma, Inc. leverages geofencing technology to boost enrollment for Phase 2 CALMA trial addressing agitation in Alzheimer's disease. Advanced outreach tools enhance patient and caregiver engagement -
-
-
COMMUNIQUÉ DE PRESSE
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
IGC Pharma, Inc. will participate in BIO Partnering @ JPM alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. The management team will showcase recent partnerships and achievements -
-
-
COMMUNIQUÉ DE PRESSE
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
IGC Pharma, Inc. expands clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease, to evaluate disease-modifying potential targeting amyloid plaque and tau tangles -
-
